BigBearai Holdings Inc vs Becton Dickinson and Co — how do they compare? BigBearai Holdings Inc trades at $3.34 (market cap $1.55B), while Becton Dickinson and Co trades at $181.29 (market cap $48.93B). The key difference: Becton Dickinson and Co is far larger — about 31.6× BigBearai Holdings Inc's market cap, and Becton Dickinson and Co pays a 2.34% dividend while BigBearai Holdings Inc pays none. Which is the better fit depends on your goals.
| BBAI | BDX | |
|---|---|---|
Market Cap | $1.55B | $48.93B |
Sector | Technology | Health |
52-Week High | $8.91 | $185.39 |
52-Week Low | $2.61 | $138.62 |
Enterprise Value | $1.25B | $65.03B |
Dividend Yield | — | 2.34% |
Signals from Pluang's Aura AI — not financial advice
BBAI trades at $3.27, up 8.64% with a bullish technical signal despite negative profitability metrics. The company reported Q2 2026 revenue growth of 13% and beat EPS estimates, though it remains unprofitable with a -65.2% net income margin. Recent news highlights defense contract execution and generative AI platform expansion for government clients.
The outlook remains challenging due to persistent losses and negative cash flow from operations, though analyst consensus leans neutral with 75% hold ratings. Key risks include execution on government contracts and achieving profitability, while technical indicators suggest near-term bullish momentum.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →